EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group



Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group



Clinical Journal of the American Society of Nephrology 1(6): 1173-1178



Children with frequently relapsing nephrotic syndrome (FRNS) often develop adverse effects from prednisone. Attempts to induce long-term remission in such patients have had varying levels of success. In this multicenter, prospective, open-label study, 14 centers enrolled 33 patients with FRNS, all of whom were in remission at the time of entry. Six of the patients were steroid dependent. The patients received mycophenolate mofetil (MMF) 600 mg/m(2) twice daily (maximum 1 g twice daily) for 6 mo. A tapering dosage of alternate-day prednisone was given to each patient during the first 16 wk of MMF therapy. Patients were monitored for relapses of NS during and after MMF therapy. Treatment failure was defined as a relapse of NS. The patients had the following features at study entry: Age 6.8 +/- 2.7 yr (range 2 to 15 yr); 56% male, 44% female; and 50% white; 25% black, and 25% other. Estimated GFR at entry was 138 +/- 42 ml/min per 1.73 m(2). Twenty-four (75%) of 32 patients stayed in remission throughout the 6 mo of MMF therapy. The relapse rate in these patients improved from one episode every 2 mo before MMF to one every 14.7 mo after MMF. Eight patients stayed in remission during the post-MMF period, for periods of 18 to 30 mo, whereas 16 relapsed after stopping MMF. Eight (25%) of 32 patients relapsed while taking MMF. It is concluded that MMF is effective for maintaining remission in patients who have FRNS and receive treatment for at least 6 mo and is associated with a low incidence of adverse events.

(PDF emailed within 0-6 h: $19.90)

Accession: 054519254

Download citation: RISBibTeXText

PMID: 17699344

DOI: 10.2215/CJN.00550206



Related references

Multicenter trial of mycophenolate mofetil in children with steroid dependent or frequent relapsing nephrotic syndrome Report of the Southwest Pediatric Nephrology Study Group. Journal of the American Society of Nephrology 14(Abstracts Issue): 751A, November, 2003

Assessment of mycophenolate mofetil for treatment of frequently relapsing nephrotic syndrome in children. Zhong Nan Da Xue Xue Bao. Yi Xue Ban 32(6): 938-940, 2008

Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. Journal of the American Society of Nephrology 24(10): 1689-1697, 2013

Mycophenolate mofetil in children with steroid-dependent and/or frequently relapsing nephrotic syndrome. Annals of Saudi Medicine 25(5): 380-384, 2005

Varicella vaccination in children with nephrotic syndrome: A report of the southwest pediatric nephrology study group. Journal of Pediatrics 142(2): 145-148, February, 2003

One-year follow-up after Varivax immunization in children with nephrotic syndrome A report of the southwest pediatric nephrology study group. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 146A, September, 2000

Safety, tolerability and immunogenicity of VARIVAX in children with nephrotic syndrome A report of the southwest pediatric nephrology study group. Pediatric Research 45(4 PART 2): 332A, April, 1999

Safety, Tolerability & Immunogenicity of Varivax in Children with Nephrotic Syndrome: A Report of the Southwest Pediatric Nephrology Study Group. Pediatric Research 45(4, Part 2 of 2): 332a-332a, 1999

Focal segmental glomerulosclerosis in children with idiopathic nephrotic syndrome. A report of the Southwest Pediatric Nephrology Study Group. Kidney International 27(2): 442-449, 1985

Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatric Nephrology 19(1): 101-104, 2004

Immunogenicity and persistence of antibody levels following VARIVAX in children and adolescents with nephrotic syndrome A report of the Southwest pediatric nephrology study group. Journal of the American Society of Nephrology 10(PROGRAM AND ABSTR ISSUE): 72A, Sept, 1999

Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome. Nephrology 21(1): 21-27, 2016

Association of IgA nephropathy with steroid-responsive nephrotic syndrome. A report of the Southwest Pediatric Nephrology Study Group. American Journal of Kidney Diseases 5(3): 157-164, 1985

Childhood nephrotic syndrome associated with diffuse mesangial hypercellularity. A report of the Southwest Pediatric Nephrology Study Group. Kidney International 24(1): 87-94, 1983

The spectrum of glomerular lesions in adolescents with nephrotic syndrome a report of the southwest pediatric nephrology study group. Pediatric Research 20(4 PART 2): 451A, 1986